CRVS vs INCY
CRVS: A clinical-stage biotechnology company developing ITK-inhibitor therapies to treat T-cell lymphomas and immune-mediated inflammatory diseases. INCY: Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions.
Side-by-side fundamentals
| Metric | CRVS | INCY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $10.21 | $112.75 | |
| Market cap | $859M | $22.5B | |
| P/E as of 2026-10-08 | n/a | 14.37 | |
| Net margin FY2025, SEC XBRL | n/a | +25.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +29.5% | |
| ROE FY2025, SEC XBRL | -25.0% | +24.9% | INCY higher |
| ROA FY2025, SEC XBRL | -21.5% | +18.5% | INCY higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.01 | CRVS lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +26.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.35 | 0.55 | |
| 1-year return as of 2026-10-08 close | +45.9% | +32.1% | CRVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.